Skip to main content

Month: January 2021

Kering: Statement in compliance with article 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)

 January 20, 2021Statement in compliance with article 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)1 Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations).2 Excluding treasury shares stripped of voting rights. AttachmentKERING – DRTSVTANG 15.01.2021

Continue reading

Kering : Publication mensuelle du nombre d’actions composant le capital et du nombre total de droits de vote (articles L. 233-8 du code de commerce et 223-16 du règlement général de l’AMF)

 Le 20 janvier 2021Publication mensuelle du nombre d’actions composant le capital et du nombre total de droits de vote (articles L. 233-8 du code de commerce et 223-16 du règlement général de l’AMF)1 Conformément à l’article 223-11 du Règlement général de l’AMF, le nombre de droits de vote théoriques est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions temporairement privées de droits de vote (actions auto-détenues).2 Déduction faite des actions privées du droit de vote. Pièce jointeKERING – DRTSVT 15.01.2021

Continue reading

Green Hygienics Holdings Inc. To Host Shareholder Update Jan. 28, 2021

SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Green Hygienics Holdings Inc. (OTCQB: GRYN) (“Green Hygienics” or the “Company”) is pleased to announce it will host a shareholder update call.The call will be facilitated by Green Hygienics’ CEO Ron Loudoun. He will be joined by COO Kyle MacKinnon. The team will provide an update on the Company’s achievements over the past year, current initiatives and projects, sales and the future road map.The call will take place on Thursday, Jan. 28, at 1 p.m. Pacific Standard Time/4 p.m. Eastern TimeInvestors, analysts and other interested parties can access the call through this Zoom Webinar link:https://zoom.us/j/98787053234?pwd=VmVnWkJHRDNRc0pBczlVZ3VFR0I3UT09Webinar ID: 987 8705 3234Passcode: 550001Or Telephone:                        (for higher...

Continue reading

Freddie Mac’s Record $83 Billion Multifamily Volume Helped Support Volatile 2020 Market

MCLEAN, Va., Jan. 20, 2021 (GLOBE NEWSWIRE) — Freddie Mac’s (OTCQB: FMCC) Multifamily line of business set a new record with $82.5 billion in loan purchase and guarantee volume in 2020. The company also provided $500 million in Low-Income Housing Tax Credit (LIHTC) equity investments, supporting underserved communities across the United States. The $83.0 billion in total production bests the company’s prior record of $78.4 billion set in 2019. Overall, the company financed roughly 803,000 rental units, more than 95% of which are affordable to families making 120% of area median income and below.“In a volatile year, Freddie Mac was a stabilizing force in the multifamily market,” said Debby Jenkins, executive vice president and head of Freddie Mac Multifamily. “The fact that we hit a record in the midst of a pandemic shows our commitment...

Continue reading

Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes

Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA).The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial,...

Continue reading

Rodrigo Martineli joins Rackspace Technology to lead Latin American Region

SAN ANTONIO, Jan. 20, 2021 (GLOBE NEWSWIRE) — Rackspace Technology™ (NASDAQ: RXT), a leading end-to-end multi-cloud technology solutions company, today announced the appointment of Rodrigo Martineli as new Latin American Vice President and General Manager, effective January 1, 2021.As Vice President and General Manager for LATAM of Rackspace Technology, the Brazilian-American executive will be responsible for leading the company’s expansion strategy, operations, and development across the region. His expertise will help Latin American customers innovate by navigating the multicloud universe with break-through models.This announcement further demonstrates the commitment that Rackspace Technology has in the LATAM market by a significant investment in the region. The launch of the new office in Colombia and the representation in Chile...

Continue reading

Værdipapirfonden Sydinvest, foreløbige udbytter for 2020

(selskabsmeddelelse 05/2021)Ledelsen i Værdipapirfonden Sydinvest har godkendt nedenstående foreløbige udlodninger fra værdipapirfondens udloddende afdelinger. De foreløbige udbytter er angivet i kr. pr. bevis:Udbytterne forventes at være på investorernes konti den 25. januar 2021. Den sidste handelsdag for andele inkl. de foreløbige udbytter ovenfor er den 20. januar 2021. Første handelsdag, hvor de foreløbige udbytter er fragået i prisen på andelene, er den 21. januar 2021.Venlig hilsenSyd Fund Management A/STlf. 74 37 33 00

Continue reading

Investeringsforeningen Sydinvest, udbetaling af foreløbige udbytter for 2020

Selskabsmeddelelse 05/2021Bestyrelsen i Investeringsforeningen Sydinvest har godkendt nedenstående foreløbige udlodninger fra foreningens udloddende afdelinger.De forventede udbytter er angivet i kr. pr. bevis:Der udbetales ikke foreløbige udbytter fra afdelinger / andelsklasser, som ikke er nævnt i tabellen ovenfor.Udbytterne forventes at være på investorernes konti den 25. januar 2021.Der vil blive tilbageholdt udbytteskat i samtlige aktiebaserede afdelinger samt afdelingerne Virksomhedsobligationer HY Etik A DKK, Virksomhedsobligationer HY A DKK, Virksomhedsobligationer IG Etik A DKK og Virksomhedsobligationer IG A DKK.Den sidste handelsdag for andele inkl. de foreløbige udbytter ovenfor er den 20. januar 2021. Første handelsdag, hvor de foreløbige udbytter er fragået i prisen på andelene, er den 21. januar 2021.Udbytterne for 2020...

Continue reading

ArcAroma AB: 210120 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag

Pressmeddelande 2021-01-20ArcAroma och OptiFreeze skapar tillsammans ett starkare bolagStyrelserna i ArcAroma AB (publ) och OptiFreeze AB (publ) beslutade igår att föreslå ett samgående mellan bolagen genom fusion. Beslutet har tagits mot bakgrund av den marknadspotential och de synergieffekter som identifierats i samband med bolagens utökade samarbetsavtal, som tecknades i november 2020.ArcAroma och OptiFreeze har i olika omfattning samarbetat sedan grundandet av OptiFreeze 2011, där ArcAroma var en av grundarna till OptiFreeze. Sedan bolagens utökade samarbete inleddes i november 2020 har marknadsmöjligheter och synergier framstått som allt tydligare om bolagens resurser och tillväxtpotential kombineras. När fusionen är genomförd är målet att inleda processen för ett listbyte till Nasdaq Stockholm Small Cap.Storleken på det fusionerade...

Continue reading

Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups

NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US, West Cancer Center of Memphis, TN; and New York Cancer & Blood Specialists of New York. During the coming weeks, both practices will be bringing Precipio’s HemeScreen technology in-house. The implementation of HemeScreen will enable these practices to significantly improve turnaround time for important molecular tests for diseases such as MPN (Myeloproliferative Neoplasms), CLL (Chronic Lymphocytic Leukemia) and AML (Acute Myeloid Leukemia), delivering better care to their cancer patients.Following the recent publication introducing HemeScreen to physician office laboratories (POLs) in ION’s Oncologists Magazine, the partnership with...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.